Caring Brands shares surge 11% premarket after securing exclusive global license for Emesyl nausea relief product.

Caring Brands Inc. (CABR) rose 11.00% in premarket trading following the announcement of an exclusive global license to manufacture, market, and distribute Emesyl, an over-the-counter nausea relief product. The agreement with Itonis Inc. grants Caring Brands full commercialization rights, leveraging a projected $6.23 billion global market for nausea treatments by 2025. The deal includes royalties on future sales and potential equity in Itonis tied to revenue milestones, aligning with the company’s strategy to expand its health and wellness portfolio. CEO Glynn Wilson highlighted the strategic significance of Emesyl’s commercial potential, underscoring the transaction’s alignment with long-term growth objectives. The move signals enhanced revenue opportunities through new product diversification and market entry, directly driving investor optimism.